According to Benzinga Pro data, during Q2, Seattle Genetics SGEN posted sales of $497.50 million. Earnings were up 1.22%, but Seattle Genetics still reported an overall loss of $134.83 million.

Despite the long history of psoriasis and psoriatic arthritis (PsA), until recently, little had been known of their underlying genetics and pathogenesis. Without this knowledge, rational clinical ...

Despite the long history of psoriatic arthritis (PsA), until recently, little had been known of its underlying genetics and pathogenesis. Without this knowledge, rational clinical management and drug ...

Examples of active research related to the estimation of heritability from SNP data, and issues related to computational efficiency, estimation of the contribution of non-additive genetic effects, and ...

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders.